DoubleLine Commercial Real Estate Debt ETF

DCRE · ETF

$50.99+$0.03 (+0.06%)TodayMarket closed ·
Prev close $50.96

About DCRE

DCRE was created on 2023-03-31 by DoubleLine. The fund's investment portfolio concentrates primarily on investment grade fixed income. The ETF currently has 442.13m in AUM and 288 holdings. DCRE is an actively managed portfolio of investment grade commercial real estate debt securities of any maturity. The fund seeks current income and capital appreciation.

Issuer
DoubleLine
Expense ratio
0.39%
Assets under management
$432.31M
Inception
Mar 31, 2023
Asset class
Fixed Income

DCRE key statistics

Price-earnings ratio
0.00
Average volume
86.30K
Volume
38.17K
Open price
$50.93
High today
$50.99
Low today
$50.89
52 Week high
$52.39
52 Week low
$50.63

DoubleLine Commercial Real Estate Debt ETF (DCRE) at a glance

As of Oct 23, 2026, DoubleLine Commercial Real Estate Debt ETF (DCRE) shares are priced at $50.99, giving the company a price-to-earnings ratio of 0.00.

Today the fund has traded between $50.89 and $50.99. The current price is 0.2% above the day's low and 0.0% below its high.

Volume so far is 38.17K shares, below the average of 86.30K shares a day.

Over the past year DoubleLine Commercial Real Estate Debt ETF has ranged from $50.63 to $52.39, and now sits 20% of the way up that range.

DCRE news

  • Rishabh Mishra

    Bond King Jeffrey Gundlach Wants Out of the AI 'Epicenter': Inside His Zero-Exposure Portfolio

  • Press releasePRNewswire

    DCRE to Change Name to DoubleLine Commercial Real Estate Debt ETF

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.